# SANA — replay s2 — bf16

## Metadata

ticker: SANA
arm: bf16
sample: 2
served_name: financial-lora
source_findings: eval/runs/raw/v924f-findings/SANA_local-model.md
context_sha256: 03e6bdab74ad2102adf024d5f44d8c25f69c6ba19acc4870607d569ceca09ae2
agent_core_sha256: f45e278f9722d5c331843a77692b154904f72edd059e6a3da48976a7945db44e
sampling: {"temperature": 0.1, "max_tokens": 512, "top_p": 0.8, "top_k": 20, "repetition_penalty": 1.1, "min_p": 0.0}
endpoint: http://localhost:30880
generated_utc: 2026-09-30T04:21:57Z
financial_health_prompt_sha256: 0a7f61736a0b9867773ff7db9508225e9a13499f7330cee4b00e8cebbb7ed76d
financial_health_seed: 20312
financial_health_response_model: financial-lora
financial_health_finish_reason: stop
financial_health_completion_tokens: 86
risk_factors_prompt_sha256: f9aa231716879b9188636cec364f613a0e910dd13e3e5de132fec68b9fe09366
risk_factors_seed: 20313
risk_factors_response_model: financial-lora
risk_factors_finish_reason: stop
risk_factors_completion_tokens: 489

## Stock data

{
  "ticker": "SANA",
  "company_name": "Sana Biotechnology, Inc.",
  "current_price": 3.08,
  "currency": "USD",
  "market_cap": 922030720.0,
  "forward_pe": -5.54845,
  "week_52_high": 6.55,
  "week_52_low": 2.61,
  "net_income": -211822000.0,
  "profit_margin": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

<!-- replay-section: Financial Health -->
### Financial Health
Sana Biotechnology, Inc., trades under the ticker symbol SANA. It is headquartered in [City Name], United States. As of March 3, 2026, the company carries a market capitalization of $92.2 billion (in USD). The forward P/E ratio as of March 3, 2026, stands at -5.5x.

<!-- replay-section: Risk Factors -->
### Primary Risk Factors Disclosed

The company faces various material risks, which can be categorized into several key areas:

#### 1. **Technology and Development Risks**
   - The company relies on innovative cell engineering platforms that are based on novel, unproven technologies. These technologies may not result in approved or marketable products.
   - The company is also subject to preclinical testing and clinical trial phases where failure to demonstrate safety, purity, potency, and efficacy could significantly impact the ability to commence these trials.

#### 2. **Financial and Operational Risks**
   - The company operates in a highly competitive environment and faces substantial financial and operational challenges. These include the need to maintain adequate liquidity and access to capital markets; the need to manage growth and expansion of operations; and the need to comply with extensive regulatory requirements and lengthy, unpredictable approval processes.
   - Additionally, the company faces risks related to human stem cell use, including ethical and legal implications. The company also faces risks related to its reliance on third-party suppliers and service providers who may experience production difficulties or other disruptions that could adversely affect the company’s business and results of operations.

#### 3. **Personnel and Strategic Risks**
   - The company depends on the continued services of certain key employees, including executive officers and senior management. The loss of the services of any such key employee could have a material adverse effect on the company’s business and results of operations.
   - The company also faces risks related to its dependence on third-party suppliers and service providers who may experience production difficulties or other disruptions that could adversely affect the company’s business and results of operations.

#### 4. **Manufacturing and Supply Chain Risks**
   - The company faces complex manufacturing processes that may encounter production difficulties. The company also faces exposure to supply chain risks for materials required in manufacturing. The company also faces reliance on third parties (CDMOs, CROs) whose failures could harm the business.

#### 5. **Regulatory, Intellectual Property, and Security Risks**
   - The company operates in a highly regulated industry and faces extensive regulatory requirements and lengthy, unpredictable approval processes. The company also faces risks related to human stem cell use, including ethical and legal implications. The company also faces risks related to its reliance on third-party suppliers and service providers who may experience production difficulties or other disruptions that could adversely affect the company’s business and results of operations.
